Printer Friendly

CORTECH BEGINS PRECLINICAL DEVELOPMENT OF COMPOUNDS FOR SULFA ALLERGY TREATMENT IN AIDS PATIENTS

 DENVER, Sept. 16 /PRNewswire/ -- Cortech Inc. (NASDAQ: CRTQ) has initiated preclinical development of a series of compounds to treat allergy to sulfamethoxazole (SMX) in AIDS patients, announced David K. Crossen, Cortech president and chief executive officer, today.
 The company recently filed a patent application with the U.S. Patent Office covering these compounds and their use. The filing is one of a number the company has submitted based on the application of the antigen specific immunomodulation (ASIM) technology.
 "This milestone is important to us," Crossen said, "because this class of compounds represents the first from our immunology project to reach preclinical development. A series of compounds that are active in animal models of sulfa allergy has been evaluated, and we expect to select a lead compound to advance into toxicity testing shortly."
 SMX, in combination with another antimicrobial, trimethoprim (TMP), is the first-line therapy for both prevention and treatment of Pneumocystis carinii pneumonia (PCP), one of the most important infectious complications of AIDS. The Centers for Disease Control currently recommends that all HIV positive individuals begin prophylaxis for PCP when their CD4 plus lymphocyte counts fall below 200, irrespective of whether the patients show symptoms. Because of its low cost, ease of administration and effectiveness, SMX/TMP is widely used under a number of trade names both for prophylaxis against PCP and for treatment of active infection.
 Unfortunately, as many as 60 percent of patients receiving SMX/TMP experience adverse reactions to the SMX component. As many as 25 percent may not tolerate the therapy, necessitating a switch to other more expensive and less effective drugs. The adverse reactions to SMX experienced by these patients are widely believed to be at least partly attributable to antibodies to SMX formed in response to the drug.
 The Cortech compounds in preclinical development have already been shown to block antibody production to SMX in animal models. In preliminary animal studies, several ASIM compounds developed by the company have eliminated existing antibody responses to SMX or prevented the anti-SMX immune response in artificially sensitized mice.
 While the animal studies are encouraging, they do not necessarily predict success in human systems. The ASIM compounds under evaluation have not undergone formal toxicity studies in animals as required by the U.S. Food & Drug Administration (FDA) before human studies can be initiated. Furthermore, no human subject has been treated with these compounds. Thus, there can be no assurance that current research and development efforts will lead to a marketable product for sulfa allergy.
 Cortech is a Denver-based biopharmaceutical company that is developing a variety of therapies for inflammatory diseases, allergies and selected autoimmune diseases.
 -0- 9/16/93
 /CONTACT: Timothy C. Rodell or David K. Crossen of Cortech, 303-650-1200/
 (CRTQ)


CO: Cortech Inc. ST: Colorado IN: MTC SU:

MC -- DV004 -- 2600 09/16/93 10:26 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 16, 1993
Words:470
Previous Article:NATIONAL TECHTEAM, INC. ANNOUNCES AGREEMENT FOR ACQUISITION OF MICRO SYSTEMS GROUP, INC.
Next Article:WACKENHUT TO CONSTRUCT, MANAGE NEW TEXAS PRISON
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters